{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:42:45Z","timestamp":1761871365503,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["16-34405A"],"award-info":[{"award-number":["16-34405A"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.clml.2019.02.005","type":"journal-article","created":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T02:43:00Z","timestamp":1550630580000},"page":"365-371","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Hematopoietic Stem Cell Transplantation From Haploidentical Donors in Aplasia After Cladribine\/Cytarabine Chemotherapy for Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4274-3895","authenticated-orcid":false,"given":"Jan","family":"Vydra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronika","family":"V\u00e1lkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbora","family":"\u010cemusov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Kol\u00e1\u0159","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludmila","family":"Nov\u00e1kov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petr","family":"Soukup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyril","family":"\u0160\u00e1lek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6905-6227","authenticated-orcid":false,"given":"Milena","family":"Vran\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Pytl\u00edk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petr","family":"Lesn\u00fd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton\u00edn","family":"V\u00edtek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petr","family":"Cetkovsk\u00fd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark\u00e9ta","family":"Markov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2019.02.005_bib1","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2014-10-551911","article-title":"How I treat refractory and early relapsed acute myeloid leukemia","volume":"126","author":"Thol","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.02.005_bib2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.leukres.2018.02.012","article-title":"AML refractory to primary induction with Ida-FLAG has a poor clinical outcome","volume":"68","author":"Kavanagh","year":"2018","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2019.02.005_bib3","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/bloodadvances.2018016121","article-title":"Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort","volume":"2","author":"Stahl","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2019.02.005_bib4","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/bmt.2016.325","article-title":"Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO)","volume":"52","author":"Todisco","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2019.02.005_bib5","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13045-017-0498-8","article-title":"Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT","volume":"10","author":"Brissot","year":"2017","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clml.2019.02.005_bib6","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1200\/JCO.2005.07.061","article-title":"Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome","volume":"23","author":"Schmid","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.02.005_bib7","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2005-10-4165","article-title":"Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation","volume":"108","author":"Schmid","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.02.005_bib8","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1007\/s00277-013-1774-5","article-title":"Allogeneic hematopoietic cell transplantation with reduced-intensity conditioning following FLAMSA for primary refractory or relapsed acute myeloid leukemia","volume":"92","author":"Schneidawind","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2019.02.005_bib9","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/bmt.2014.328","article-title":"Sequential therapy combining clofarabine and T-cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma","volume":"50","author":"Zoellner","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2019.02.005_bib10","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2019.02.005_bib11","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.bbmt.2014.01.019","article-title":"Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation Practice Guideline Committee","volume":"20","author":"Bubalo","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2019.02.005_bib12","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2019.02.005_bib13","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/bmt.2016.130","article-title":"Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation","volume":"51","author":"Mohty","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2019.02.005_bib14","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A\u00a0note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.clml.2019.02.005_bib17","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1182\/blood-2010-05-283051","article-title":"Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia","volume":"116","author":"Cooley","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.02.005_bib18","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.02.005_bib19","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1200\/JCO.2011.37.1286","article-title":"Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study","volume":"30","author":"Holowiecki","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.02.005_bib20","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.leukres.2016.04.015","article-title":"CLAG-based induction therapy in previously untreated high risk acute myeloid leukemia patients","volume":"46","author":"Seiter","year":"2016","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2019.02.005_bib21","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.leukres.2010.09.002","article-title":"Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens","volume":"35","author":"Price","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2019.02.005_bib22","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s00277-016-2774-z","article-title":"Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia","volume":"95","author":"Park","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2019.02.005_bib23","doi-asserted-by":"crossref","first-page":"e706","DOI":"10.1097\/MD.0000000000000706","article-title":"Busulfan and fludarabine conditioning regimen given at hematological nadir of cytoreduction fludarabine, cytarabine, and idarubicin chemotherapy in patients with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation","volume":"94","author":"Tang","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clml.2019.02.005_bib24","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1007\/s00277-018-3453-z","article-title":"Sequential treatment combining cladribine-based re-induction, myeloablative allogeneic HSCT, and prophylactic donor lymphocyte infusion: a promising treatment for refractory acute myeloid leukemia","volume":"97","author":"Xiao","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2019.02.005_bib25","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/cncr.30536","article-title":"Allogeneic transplantation for advanced acute myeloid leukemia: the value of complete remission","volume":"123","author":"Weisdorf","year":"2017","journal-title":"Cancer"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018315416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018315416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:33:19Z","timestamp":1761870799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265018315416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S2152265018315416"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.02.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hematopoietic Stem Cell Transplantation From Haploidentical Donors in Aplasia After Cladribine\/Cytarabine Chemotherapy for Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}